{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:05:40Z","timestamp":1783951540296,"version":"3.55.0"},"reference-count":38,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,8]]},"abstract":"<jats:p> PURPOSE: To evaluate response and outcome with a front-line intensive multiagent chemotherapy regimen in adults with Burkitt's-type acute lymphoblastic leukemia (B-ALL). <\/jats:p><jats:p> PATIENTS AND METHODS: From September 1992 to June 1997, 26 consecutive adults with newly diagnosed untreated B-ALL received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD). Their median age was 58 years (range, 17 to 79 years), and 46% were \u2265 60 years. Patients received Hyper-CVAD alternated with courses of high-dose methotrexate and cytarabine. Granulocyte colony-stimulating factor and prophylactic antibiotics were administered for all eight planned courses. CNS prophylaxis alternated intrathecal methotrexate and cytarabine on days 2 and 7 of each course. <\/jats:p><jats:p> RESULTS: Complete remission (CR) was obtained in 21 patients (81%). There were five induction deaths (19%). The median time to CR was 22 days (range, 15 to 89 days); 70% achieved CR within 4 weeks. The 3-year survival rate was 49% (\u00b1 11%); the 3-year continuous CR rate was 61% (\u00b1 11%). Twelve CR patients (57%) were in continuous CR at a median follow-up of 3+ years (range, 13+ months to 6.5+ years). Characteristics predicting for worse survival were age \u2265 60 years, poor performance status, anemia, thrombocytopenia, peripheral blasts, and increased lactate dehydrogenase level. The 3-year survival rate was 77% for 14 patients younger than 60 years and 17% for 12 patients \u2265 60 years (P &lt; .01). Regression analysis identified older age, anemia, and presence of peripheral blasts as independent factors associated with shorter survival. Patients could be stratified according to (1) no or one adverse feature, (2) two adverse features, and (3) all adverse features. The 3-year survival rates were 89%, 47%, and 0%, respectively (P &lt; .01). <\/jats:p><jats:p> CONCLUSION: Hyper-CVAD is effective in adult B-ALL. Identification of patients with high risk for relapse and improved methods to detect residual disease may result in risk-oriented approaches. <\/jats:p>","DOI":"10.1200\/jco.1999.17.8.2461","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:19:51Z","timestamp":1487917191000},"page":"2461-2461","source":"Crossref","is-referenced-by-count":218,"title":["Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic Leukemia"],"prefix":"10.1200","volume":"17","author":[{"given":"Deborah A.","family":"Thomas","sequence":"first","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, and Department of Hematology and Oncology, Children's Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, and Department of Hematology and Oncology, Children's Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, and Department of Hematology and Oncology, Children's Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, and Department of Hematology and Oncology, Children's Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, and Department of Hematology and Oncology, Children's Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Albitar","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, and Department of Hematology and Oncology, Children's Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick B.","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, and Department of Hematology and Oncology, Children's Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando F.","family":"Cabanillas","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, and Department of Hematology and Oncology, Children's Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Murphy","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, and Department of Hematology and Oncology, Children's Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, and Department of Hematology and Oncology, Children's Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Hematopathology, and Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, and Department of Hematology and Oncology, Children's Memorial Hospital of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-2461","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1976.tb03563.x"},{"key":"R2-2461","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.2.415.415"},{"key":"R3-2461","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.11.3995"},{"key":"R4-2461","unstructured":"Hammami  A,  Chan  WC,  Michels  SD, et al: Mature B-cell acute leukemia: A clinical, morphological, immunological, and cytogenetic study of nine cases.  Hematologic Pathol 5:109,1991-118,"},{"key":"R5-2461","unstructured":"Finlay  JL,  Borcherding  W: Acute B-lymphocytic leukemia with L1 morphology: A report of two pediatric cases.  Leukemia 2:60,1988-62,"},{"key":"R6-2461","unstructured":"Gladstone  B,  Kadam  PR,  Balsara  BR, et al: Cytogenetic studies on patients of acute lymphoblastic leukemia Burkitt's type with (8;14) & (14;18) translocations.  Indian J Med Res 99:264,1994-266,"},{"key":"R7-2461","unstructured":"Stamatoullas  A,  Bastard  C,  Lesesve  JF, et al: Acute B-cell leukemia with t(14;18).  Blood 90:503,1997,  (abstr 2243)"},{"key":"R8-2461","unstructured":"Velangi  M,  Jackson  G,  Bown  N, et al: Pattern of cytogenetics in the northern region 1983-1997.  Br J Haematol 102:108,1998,  (abstr 425)"},{"key":"R9-2461","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V60.3.677.bloodjournal603677"},{"key":"R10-2461","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(82)90190-0"},{"key":"R11-2461","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.6.994"},{"key":"R12-2461","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04982.x"},{"key":"R13-2461","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.5.737"},{"key":"R14-2461","unstructured":"Bernasconi  C,  Brusamolino  E,  Pagnucco  G, et al: Burkitt's lymphoma\/leukemia: A clinico-pathologic study on 24 adult patients.  Leukemia 5:90,1991-94,  (suppl 1)"},{"key":"R15-2461","unstructured":"Ostronoff  M,  Soussain  C,  Zambon  E, et al: Burkitt's lymphoma in adults: A retrospective study of 46 cases.  Nouv Rev Fr Hematol 34:389,1992-397,"},{"key":"R16-2461","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495"},{"key":"R17-2461","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.123"},{"key":"R18-2461","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.8.1219"},{"key":"R19-2461","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.2.359"},{"key":"R20-2461","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.10.2471.2471"},{"key":"R21-2461","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb06368.x"},{"key":"R22-2461","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.12.1732"},{"key":"R23-2461","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1252"},{"key":"R24-2461","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.3.664.bloodjournal853664"},{"key":"R25-2461","doi-asserted-by":"crossref","unstructured":"Fenaux  P,  Lai  JL,  Miaux  O, et al: Burkitt cell acute leukaemia (L3 ALL) in adults: A report of 18 cases.  Br J Haematol 71:371,1989-376,","DOI":"10.1111\/j.1365-2141.1989.tb04294.x"},{"key":"R26-2461","unstructured":"Cortes  J,  Koller  C,  Thomas  D, et al: Treatment of AIDS-related Burkitt's leukemia or lymphoma with the hyper-CVAD regimen.  Blood 92:401,1998,  (abstr 1656)"},{"key":"R27-2461","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.6.2091.bloodjournal8662091"},{"key":"R28-2461","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R29-2461","doi-asserted-by":"crossref","unstructured":"Cox  DR: Regression models and life tables.  J R Stat Soc [B] 34:187,1972-220,","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"R30-2461","doi-asserted-by":"crossref","unstructured":"Kornblau  SM,  Goodacre  A,  Cabanillas  F: Chromosomal abnormalities in adult non-endemic Burkitt's lymphoma and leukemia: 22 new reports and a review of 148 cases from the literature.  Hematol Oncol 9:63,1991-78,","DOI":"10.1002\/hon.2900090202"},{"key":"R31-2461","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830350316"},{"key":"R32-2461","unstructured":"Advani  Sh,  Ahuya  HG,  Gopal  R, et al: Clinical and phenotypic heterogeneity in L3-acute lymphoblastic leukemia.  Indian J Cancer 25:108,1988-113,"},{"key":"R33-2461","unstructured":"Lai  JL,  Fenaux  P,  Zandecki  M, et al: Cytogenetic studies in 30 patients with Burkitt's lymphoma or L3 acute lymphoblastic leukemia with special reference to additional chromosome abnormalities.  Ann Genet 32:26,1989-32,"},{"key":"R34-2461","unstructured":"Goldie  JH,  Coldman  AJ: The genetic origin of drug resistance in neoplasm: Implications for systemic therapy.  Cancer Res 44:3643,1984-3653,"},{"key":"R35-2461","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008214203225"},{"key":"R36-2461","unstructured":"Kantarjian  H,  O'Brien  S,  Keating  MJ, et al: Update of the hyper-CVAD dose-intensive regimen in adult acute lymphocytic leukemia.  Blood 92:313,1998,  (abstr 1285)"},{"key":"R38-2461","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.9.2465"},{"key":"R40-2461","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.5.809"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.8.2461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:28:49Z","timestamp":1653514129000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.8.2461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[1999,8]]}},"alternative-id":["10.1200\/JCO.1999.17.8.2461"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.8.2461","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,8]]}}}